Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

CAR-T Digest - August 2020

Weekly Digest - June 2025

02 June 2025: Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Eli Lilly’s FRα-targeting ADC (LY4170156) showed promising safety and efficacy in a Phase 1 trial involving heavily pre-treated patients with platinum-resistant ovarian cancer, including those previously treated with Mirvetuximab soravtansine
The antibody-drug conjugate demonstrated anti-tumor activity across all dose levels and FRα expression levels, with a 55% objective response rate (ORR) at the potential Phase 2 dose (4 mg/kg) and a 45% ORR overall among efficacy-evaluable patients
Based on these early results, Lilly plans to advance LY4170156 into Phase 3 clinical trials, aiming to expand treatment options for a broader population of ovarian cancer patients regardless of FRα expression